ArticleClinical kidney journal2026
Pre-existing anxiety and mood disorders and multisystem outcomes in young adults with chronic kidney disease.
Article in Clinical kidney journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Anxiety and mood disorders (AMD) are common in young adults and may amplify medical risk in chronic kidney disease (CKD). However, their prognostic impact in young adults with moderate-severe CKD remains poorly defined. We investigated whether pre-existing AMD identify a subgroup of young CKD patients at increased risk of adverse clinical outcomes. Methods: Using the TriNetX Global Collaborative Network, we identified young adults aged 18-30 years with stage 3-4 CKD documented in the Electronic Health Records. Patients with documented AMD prior to CKD identification were compared with those without AMD. Cohorts were balanced using 1:1 propensity score matching. Time-to-event outcomes were analyzed using Kaplan-Meier methods and Cox proportional hazards models. Prespecified sensitivity analyses included restriction to patients with documented body mass index and a landmark analysis with delayed outcome assessment to address surveillance bias and follow-up heterogeneity. Results: Among 3876 eligible patients, 1356 had pre-existing AMD. After matching, 734 patients remained in each cohort. Over follow-up, AMD was associated with higher risks of cardiovascular outcomes (ischemic heart disease, arrhythmias, stroke, hypotension), renal outcomes (acute kidney injury, progression to dialysis), pneumonia, neurocognitive complications (acute confusional state, encephalopathy), and sleep disorders. In the primary matched analysis, all-cause mortality did not differ between groups [hazard ratio (HR) 1.00, 95% confidence interval (CI) 0.72-1.39]. In prespecified sensitivity analyses restricted to patients with sustained follow-up and delayed outcome assessment, AMD was associated with higher mortality risk (HR 1.92, 95% CI 1.21-3.03). Conclusions: In young adults with stage 3-4 CKD, pre-existing AMD identify a phenotype associated with increased multisystem morbidity. Although no difference in mortality was observed in the primary analysis, sensitivity analyses suggest a potential association with excess mortality among patients with sustained follow-up. These findings support integrating mental health assessment into CKD risk stratification and highlight the need for prospective studies on the long-term survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.